Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline

April 1, 2026 5:41 PM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $220.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found